Effect of Adjunctive Celecoxib on BDNF in Manic Patients Undergoing Electroconvulsive Therapy: a Randomized Double Blind Controlled Trial

M. Kargar; A. Yoosefi; S. Akhondzadeh; V. Artonian; A. Ashouri; P. Ghaeli

doi:10.1055/s-0035-1559667

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2015; 48(07): 268-273
DOI: 10.1055/s-0035-1559667

Original Paper

Effect of Adjunctive Celecoxib on BDNF in Manic Patients Undergoing Electroconvulsive Therapy: a Randomized Double Blind Controlled Trial

Authors

M. Kargar

¹Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
A. Yoosefi

²Amiralam Hospital, Department of Anesthesiology, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
S. Akhondzadeh

³Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences,Tehran, Iran, Islamic Republic of
V. Artonian

⁴Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
A. Ashouri

⁵School of public health, Department of epidemiology and biostatistics, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
P. Ghaeli

⁶Faculty of Pharmacy & Psychiatry and Psychology Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of

Abstract

Introduction: The possible effect of inflammatory factors on decreasing BDNF has been proposed in the literature. There is conflicting evidence regarding association between BDNF level alteration and treatment response in depressive patients undergoing electroconvulsive therapy (ECT). This study investigated the effects of celecoxib in manic patients undergoing ECT on treatment response and BDNF levels.

Methods: This randomized, double-blind, clinical trial included 35 manic patients who received either celecoxib (200 mg twice daily) or placebo, from one day before the 1^st ECT session throughout the 6^th session. BDNF levels were measured at baseline, 1^st, 3^rd and 6^th ECT sessions. Young mania rating scale was used to assess treatment response.

Results: Adding celecoxib was not associated with a significant rise in BDNF levels following ECT. No difference was noted between groups in terms of treatment response. No significant association was found between changes in BDNF levels and patients’ responses.

Discussion: Adjuvant celecoxib did not significantly affect the BDNF level or the treatment response following ECT in manic patients.

Key words

bipolar disorder - electroconvulsive therapy (ECT) - bipolar disorder treatment

Full Text

References

References
1 Zhang X, Zhang Z, Sha W et al. Effect of treatment on serum glial cell line-derived neurotrophic factor in bipolar patients. J Affect Disord 2010; 126: 326-329
2 de Oliveira GS, Ceresér KM, Fernandes BS et al. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. J Psychiatr Res 2009; 43: 1171-1174
3 Dias VV, Brissos S, Frey BN et al. Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. Bipolar Disord 2009; 11: 663-671
4 Fernandes BS, Gama CS, Walz JC et al. Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes. J Psychiatr Res 2010; 44: 561-565
5 Berk M, Malhi GS, Hallam K et al. Early intervention in bipolar disorders: Clinical, biochemical and neuroimaging imperatives. J Affect Disord 2009; 114: 1-13
6 Machado-Vieira R, Dietrich MO, Leke R et al. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry 2007; 61: 142-144
7 Fernandes BS, Gama CS, Maria Ceresér K et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: A systematic review and meta-regression analysis. J Psychiatr Res 2011; 45: 995-1004
8 Coyle JT, Duman RS. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 2003; 38: 157-160
9 Sartorius A, Hellweg R, Litzke J et al. Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry 2009; 42: 270-276
10 Pillai A, Kale A, Joshi S et al. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int J Neuropsychopharmacol 2010; 13: 535-539
11 Béjot Y, Mossiat C, Giroud M et al. Circulating and brain BDNF levels in stroke rats. Relevance to clinical studies. PLoS One 2011; 6: e29405
12 Barbosa IG, Huguet RB, Mendonça VA et al. Increased plasma levels of brain-derived neurotrophic factor in patients with long-term bipolar disorder. Neurosci Lett 2010; 475: 95-98
13 Cunha AB, Frey BN, Andreazza AC et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 2006; 398: 215-219
14 Okamoto T, Yoshimura R, Ikenouchi-Sugita A et al. Efficacy of electroconvulsive therapy is associated with changing blood levels of homovanillic acid and brain-derived neurotrophic factor (BDNF) in refractory depressed patients: A pilot study. Prog Neuropsychoparmacol Biol Psychiatry 2008; 32: 1185-1190
15 Karamustafalioglu N, Genc A, Kalelioglu T et al. Plasma BDNFs level initially and post treatment in acute mania: comparison between ECT and atypical antipsychotic treatment and healthy controls. J Psychopharmacol 2015; 0269881115578161
16 Fernandes BS, Massuda R, Torres M et al. Improvement of schizophrenia with electroconvulsive therapy and serum brain-derived neurotrophic factor levels: Lack of association in a pilot study. Psychiatry Clin Neurosc 2010; 64: 663-665
17 Sayyah M, Boostani H, Pakseresht S et al. A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder. Psychiatry Res 2011; 189: 403-406
18 Akhondzadeh S, Tabatabaee M, Amini H et al. Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial. Schizophrenia Res 2007; 90: 179-185
19 Nery FG, Monkul ES, Hatch JP et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Human Psychopharmacol 2008; 23: 87-94
20 Akhondzadeh S, Jafari S, Raisi F et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009; 26: 607-611
21 Müller N, Schwarz M, Dehning S et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006; 11: 680-684
22 Müller N, Krause D, Dehning S et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophrenia Res 2010; 121: 118
23 Abbasi SH, Hosseini F, Modabbernia A et al. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord 2012; 141: 308-314
24 Kargar M, Yousefi A, Mojtahedzadeh M et al. Effects of celecoxib on inflammatory markers in bipolar patients undergoing electroconvulsive therapy: a placebo-controlled, double-blind, randomised study. Swiss Med Wkly 2014; 144: w13880
25 Bresee CJ, Delrahim K, Maddux RE et al. The effects of celecoxib augmentation on cytokine levels in schizophrenia. Int J Neuropsychopharmacol 2006; 9: 343-348
26 Funakoshi-Tago M, Shimizu T, Tago K et al. Celecoxib potently inhibits TNFα-induced nuclear translocation and activation of NF-κB. Biochem Pharmacol 2008; 76: 662-671
27 Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 2011; 130: 226-238
28 Bus B, Molendijk M, Penninx B et al. Determinants of serum brain-derived neurotrophic factor. Psychoneuroendocrinology 2011; 36: 228-239
29 Bus BA, Tendolkar I, Franke B et al. Serum brain-derived neurotrophic factor: determinants and relationship with depressive symptoms in a community population of middle-aged and elderly people. World J Biol Psychiatry 2012; 13: 39-47
30 Kapczinski F, Dias VV, Kauer-Sant’Anna M et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuropsychoparmacol Biol Psychiatry 2009; 33: 1366-1371
31 Grande I, Fries GR, Kunz M et al. The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry Investig 2010; 7: 243-250
32 Bocchio-Chiavetto L, Zanardini R, Bortolomasi M et al. Electroconvulsive therapy (ECT) increases serum brain-derived neurotrophic factor (BDNF) in drug-resistant depressed patients. Eur Neuropsychopharmacol 2006; 16: 620-624
33 Fernandes B, Gama CS, Massuda R et al. Serum brain-derived neurotrophic factor (BDNF) is not associated with response to electroconvulsive therapy (ECT): a pilot study in drug resistant depressed patients. Neurosci Lett 2009; 453: 195-198
34 Brunoni AR, Baeken C, Machado-Vieira R et al. BDNF blood levels after electroconvulsive therapy in patients with mood disorders: a systematic review and meta-analysis. World J Biol Psychiatry 2014; 15: 411-418
35 Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008; 11: 1169-1180
36 Tramontina JF, Andreazza AC, Kauer-Sant’Anna M et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci Lett 2009; 52: 111-113